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We estimated the survival and hospitalization among
frequent hemodialysis users in comparison to those patients
undergoing thrice-weekly conventional hemodialysis.
All patients had similar characteristics and medical histories.
In this cohort study of frequent hemodialysis users and
propensity score–matched controls, the collaborating
clinicians identified 94 patients who used nocturnal
hermodialysis (NHD) and 43 patients who used short-duration
daily hemodialysis (SDHD) for a minimum of 60 days. Ten
propensity score–matched control patients for each NHD and
SDHD patient were identified from the United States Renal
Data System database. Primary outcomes were risk for
all-cause mortality and risk for the composite outcome of
mortality or major morbid event (acute myocardial infarction
or stroke) estimated using Cox proportional hazards models.
Risks for all-cause, cardiovascular-related, infection-related,
and vascular access–related hospital admissions were also
studied. Nocturnal hemodialysis was associated with
significant reductions in mortality risk and risk for mortality or
major morbid event when compared to conventional
hemodialysis. There was a reduced but non-significant risk
of death for patients using SDHD compared to controls.
All-cause and specific hospitalizations did not differ
significantly between NHD and SDHD patients and their
matched control cohorts. Our study suggests that NHD may
improve patient survival.
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In the United States, the number of programs offering
nocturnal hemodialysis (NHD) therapy is reported to have
increased from 73 in 2004 to 300 in 2008, and the number of
programs offering short-duration daily hemodialysis (SDHD)
therapy is reported to have increased from 37 in 2004 to 480
in 2008.1 There is great interest in the outcomes of patients
undergoing these frequent hemodialysis (HD) regimens,
which are believed to be more physiological and better
tolerated by patients than conventional thrice weekly HD.
Frequent HD regimens, in which there is increased
frequency and/or increased duration of dialysis,2 have the
potential to increase longevity and reduce hospitalization as
compared with conventional HD (CHD). Unfortunately,
selection bias has confounded many reports on the outcomes
associated with frequent HD regimens.3–8 There is little
information about survival and hospitalization outcomes
among users of frequent HD regimens compared with
controls who have similar demographic characteristics and
medical histories.
We used the USRDS database to examine mortality
and hospitalization outcomes for patients from multiple
programs who used NHD or SDHD for at least 60 days
compared with outcomes for patients with similar charac-
teristics treated by thrice weekly CHD who were identified by
propensity score (PS) matching from the USRDS database.
We examined outcomes separately for patients using NHD
and SDHD because these are not equivalent therapies.9 The
primary research question was the risk for mortality among
NHD users compared with that among CHD controls, and
among SDHD users compared with that among CHD
controls. We also investigated a composite outcome of risk
for mortality or a major morbid event, that is, acute
myocardial infarction (AMI) or stroke, as recommended by
Chertow,10 and explored risks for all-cause and specific types
of hospitalization.
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RESULTS
All NHD and SDHD patients dialyzed 5 or 6 days a week; the
mean (s.d.) days/week for NHD patients was 5.7 (0.44) and
the mean (s.d.) days/week for SDHD patients was 5.4 (0.50)
(Table 1). Specifically, 69 NHD patients were reported to
dialyze 6 days/week and 25 were reported to dialyze 5 days/
week. Among the SDHD patients, 19 were reported to dialyze
6 days/week and 24 were reported to dialyze 5 days/week. All
NHD and SDHD patients dialyzed at home; 1% of CHD
patients used home HD as of 1 January 2003. Most patients
converted to a frequent HD regimen from conventional
center HD or conventional home HD; two patients converted
from continuous ambulatory peritoneal dialysis and con-
tinuous cycling peritoneal dialysis, respectively. The mean age
at which patients switched to NHD therapy was 51.7 (range
23.5–81.5) years and the mean age at which patients switched
to SDHD therapy was 48.0 (range 14.2–78.6) years. Patients
used NHD or SDHD for a median of 985 days.
The NHD patients and controls were similar on all
variables used for PS matching (Table 2). SDHD patients and
PS-matched controls were also similar on all variables used
for PS matching (Table 2). The majority of patients in both
frequent HD cohorts were men and white. Few patients who
initiated frequent HD regimens were characterized by lower
income, based on Medicaid coverage at treatment start as an
indicator of financial status. Both cohorts had a low average
number of cardiovascular conditions at the start of ESRD
treatment, but patients who initiated NHD were more likely
than patients who initiated SDHD to have coronary artery
disease at treatment start.
The observed mortality rates for NHD controls and
SDHD controls were 154 and 139, respectively, per 1000
patient-years. For NHD patients and SDHD patients, the
respective observed mortality rates were 74 and 91 per 1000
patient-years. Multivariable Cox proportional hazards regres-
sion analyses indicated that NHD compared with CHD was
associated with a significantly reduced hazard for death
(hazard ratio 0.36; confidence interval 0.22–0.61; P¼ 0.0001)
(Table 3). There was a reduced but non-significant risk of
death for SDHD compared with that for CHD (hazard ratio
0.64; confidence interval 0.31 to 1.31; P¼ 0.22) (Table 3).
Corresponding results from Kaplan–Meier analyses of
survival among NHD patients and CHD controls, and
survival among SDHD patients and CHD controls, are
shown in Figure 1 and Figure 2, respectively. Additional
multivariable Cox proportional hazards regression analyses
indicated that NHD compared with CHD was associated
with a significantly reduced hazard for death or major
morbid event, that is, AMI or stroke (hazard ratio 0.56;
confidence interval 0.35 to 0.89; P¼ 0.01). Among SDHD
users, the hazard ratio for death or major morbid event
compared with that among CHD was 0.83; confidence
interval 0.42 to 1.65; P¼ 0.60. For both analyses involving the
SDHD cohort, analyses restricted to early or late periods of
follow-up gave similar results; neither the early nor the late
hazard ratio achieved statistical significance, and the average
hazard ratio was similar to the hazard ratio reported in
Table 3.
Multivariable Cox regression analyses did not show that
NHD or SDHD was associated with significantly reduced
hazard for all-cause hospitalization, non-vascular access–
related hospitalization, cardiovascular hospitalization, or
infection-related hospitalization. For hospitalization asso-
ciated with congestive heart failure specifically, the hazard
ratio for NHD compared with that for CHD was 0.87;
confidence interval 0.42 to 1.81; P¼ 0.71, and the hazard
ratio for SDHD compared with that for CHD was 0.77;
confidence interval 0.23 to 2.53; P¼ 0.66. For vascular access–
related hospitalization, the hazard ratio for NHD compared
with that for CHD was 1.31; confidence interval 0.88 to 1.94;
P¼ 0.18, and the hazard ratio for SDHD compared with that
for CHD was 0.71; confidence interval 0.31 to 1.64; P¼ 0.43.
DISCUSSION
Our study showed a survival benefit of NHD compared with
CHD in a relatively modern cohort assembled from multiple
centers in the United States in which patients received NHD 5
or 6 nights/week. The annual mortality rate for the NHD
cohort was 7%. We know of no other studies that have
reported survival outcomes for NHD patients receiving
treatment 5–6 nights/week. Improved survival for patients
receiving NHD 3 nights/week has been reported by Charra
et al.11 and Ok et al.,12 but neither of these studies compared
the outcomes of NHD users with those of a propensity-
matched comparison cohort in which multiple variables were
included in the matching as we have done in this study.
Improved survival associated with NHD is biologically
plausible. Multiple clinical benefits associated with frequent
HD have been documented. Many of these benefits would
be expected to enhance survival, including reduction in left
ventricular hypertrophy,13–15 correction of sleep apnea,16 and
improved control of hypertension, mineral metabolism,
endocrine abnormalities, and anemia.17,18 Improvements in
patients’ blood pressure,6,19 hemoglobin,20 homocysteine,21
Table 1 | Dialysis treatment characteristics
NHD (n=94) SDHD (n=43) CHDa
Session time (h)
Mean (s.d.) 7.5 (0.82) 2.9 (0.59) 3
Median 8 2.83
Range (4.5, 8) (1.67, 4) (2.5, 4)
Sessions per week (days)
Mean (s.d.) 5.7 (0.44) 5.4 (0.50) 3.5
Median 6 5
Range (5, 6) (5, 6) (2, 4)
Blood flow (ml/min; range) 200–300 250–500 250–500
Dialysate flow (ml/min; range) 200–300 300–800 500–800
SpKt/V per session 1.10–1.80 0.38–1.26 1.55
CHD, conventional hemodialysis; NHD, nocturnal hemodialysis; SDHD, short-
duration daily hemodialysis.
aStandard hemodialysis prescription; Kt/V value is the mean observed for the 2006
Clinical Performance Measures sample (www.cms.hhs.gov/cpmproject/
downloads:CPM Project Year 2007 Report).
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calcium/phosphorus product,6 and Kt/V,19 as well as in
patient-assessed quality of life6,19 have been identified by
clinicians who contributed to this study.
The current analysis shares some of the limitations of
earlier studies, including low power as previously mentioned
as well as potential confounding resulting from patient
selection. Although patient selection strategies differ across
centers and over time, patient selection is clearly evident in
most reports of frequent HD strategies. Patients starting
NHD or SDHD who were identified for our study were
younger, less likely to be lower income and less likely to have
diabetic ESRD than the overall HD population in the United
States, and were characterized by fewer cardiovascular
comorbidities than patients in the overall HD population
(data not shown). We used PS matching to identify CHD
control patients with demographic, clinical, and hospitaliza-
tion history characteristics similar to NHD and SDHD users
in each of these cohorts. We believe that our PS matching,
and in particular the incorporation of matching based on
earlier hospitalization rates, is a significant advance over
previous attempts to compare outcomes between patients
receiving frequent HD and those receiving CHD. Further-
more, the matching strategy resulted in control groups with
similar vintage and earlier hospitalization rates. Nevertheless,
any matching strategy is only as good as the data available on
which to match, and patients who are considered appro-
priate for a home-based regimen such as NHD are likely to
be different than in-center dialysis patients receiving CHD,
Table 2 | Characteristics of NHD study cohort and CHD controls, and characteristics of SDHD study cohort and CHD controls
NHD
(n=94)
CHD Controls
(n=940) P-value
SDHD
(n=43)
CHD controls
(n=430) P-value
Age (year, mean (s.d.))a 47.0 (16.3) 46.7 (17.5) 0.87 40.9 (17.3) 42.2 (19.1) 0.68
Age (%) 0.98 0.87
o37 29.8 30.4 44.2 42.3
(37, 54) 34.0 34.5 32.6 30.7
X54 36.2 35.1 23.3 27.0
Male (%) 64.9 66.0 0.84 72.1 68.8 0.66
Race (%) 0.82 0.84
Native American 0.0 0.0 0.0 3.0
Black 24.5 23.4 18.6 18.6
White 75.5 76.6 72.1 70.2
Asian 0.0 0.0 7.0 5.8
Other 0.0 0.0 2.3 2.3
Medicaid coveragea 7.0 7.7 0.85 11.4 13.2 0.77
Number of cardiovascular
conditions (mean (s.d.))a
0.6 (0.9) 0.7 (1.1) 0.75 0.4 (0.9) 0.4 (0.8) 0.72
CHF (%) 17.9 23.6 0.24 11.8 14.9 0.62
CAD (%) 23.8 17.4 0.14 11.8 10.2 0.77
CVD (%) 7.1 5.0 0.39 2.9 2.5 0.87
PVD (%) 6.0 10.3 0.20 5.9 8.5 0.59
BMI (mean (s.d.))a 28.9 (8.2) 29.1 (8.7) 0.85 25.8 (7.2) 25.3 (6.1) 0.71
BMI (%) 0.70 0.96
o19 5.2 7.5 14.3 12.3
(19, 25) 32.5 29.5 42.9 42.7
X25 62.3 63.0 42.9 45.0
Diabetic ESRD (%) 27.4 28.3 0.85 25.7 27.1 0.86
Months on dialysis (mean (s.d.))b 56.3 (66.0) 52.8 (57.4) 0.58 85.5 (87.3) 81.1 (77.9) 0.73
Months on dialysis 0.13 0.76
o22 43.6 37.0 30.2 25.1
(22, 65) 25.5 35.9 27.9 28.8
X65 30.9 27.1 41.9 46.1
All-cause hospital admissions/person-yearc 1.1 0.9 0.61 0.6 0.7 0.74
All-cause hospital days/person-yearc 5.8 5.6 0.96 3.1 3.2 0.83
Cardiovascular admissions/person-yearc 0.4 0.3 0.73 0.1 0.1 1.00
Cardiovascular hospital days/person-yearc 2.0 1.8 0.81 0.4 0.5 0.87
Vascular access admissions/person-yearc 0.08 0.05 0.49 0.1 0.2 0.52
Vascular access hospital days/person-yearc 0.3 0.2 0.46 0.3 0.4 0.67
BMI, body mass index; CAD, coronary artery disease; CHF, congestive heart failure; CVD, cerebral vascular disease; ESRD, end-stage renal disease; NHD, nocturnal hemodialysis;
PVD, peripheral vascular disease; SDHD, short-duration daily hemodialysis.
aAs of ESRD treatment start, recorded in Medical Evidence Form.
bAs of conversion to NHD or SDHD: for CHD patients, as of 1 January 2003.
cDuring 365 days before NHD or SDHD conversion: for CHD patients, during 365 days before 1 January 2003.
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raising the strong possibility of residual confounding.
Specifically, we lacked data on several important potential
predictors of survival and hospitalization, such as type of
vascular access, recent laboratory parameters, and patient
adherence to dialysis. However, it is important to consider
that, although the select nature of patients appropriate for
home dialysis makes them difficult to compare with CHD
patients, these selection issues reflect actual practice and are
not likely to disappear even if a concerted effort is made to
increase the use of frequent HD. Similar to peritoneal
dialysis, it is likely that a majority of home-based frequent
dialysis therapy users will be younger and more stable, and
have higher socioeconomic status than in-center dialysis
patients.
We did not find significantly better survival among SDHD
patients when compared with PS-matched CHD control
subjects, although the point estimate of the hazard ratio in
our analysis is in accordance with data from Kjellstrand
et al.22 and Blagg et al.,23 who reported a lower mortality on
SDHD compared with matched patients in the USRDS
database, after adjustment for age, sex, race, and the presence
of diabetes. In a multicenter study of 72 patients receiving
SDHD from 1972 to 1996 for 5–7 days/week, Woods et al.24
reported a patient survival of 93% at 2 years. For 42 patients
using SDHD 5–7 days/week, Ting et al.5 reported a
cumulative survival of 33% at 6 years. For 26 patients treated
by SDHD 6 times/week for a mean (s.d.) of 33.6 (18.5)
months, Castro et al.25 reported 100% survival. None of the
latter three studies included a control group of CHD patients.
We believe that the main reason for our not observing
significantly prolonged survival in our SDHD cohort was low
statistical power.
We did not detect a reduction in hospitalization rates
related to changing to either SDHD or NHD, contrary to
reports by Ting et al.5 for SDHD and several groups of
investigators for NHD.6,7,26,27 We believe that patient
Table 3 |Multivariable Cox proportional hazard models predicting HD patient risk for mortality and risk for composite
end point of mortality/major morbid event (AMI, stroke)
NHD cohort and controls SDHD cohort and controls
Risk factor
All-cause mortality
hazard ratio (95% CI)
Mortality/AMI, stroke
hazard ratio (95% CI)
All-cause mortality
hazard ratio (95% CI)
Mortality/AMI, stroke
hazard ratio (95% CI)
Age (reference o37) 1.00 1.00 1.00 1.00
(37, 54) 0.98 (0.77, 1.25) 1.05 (0.83, 1.34) 1.21 (0.87, 1.70) 1.10 (0.78, 1.57)
X54 1.85 (1.45, 2.35)* 2.39 (1.87, 3.05)* 2.33 (1.64, 3.30)* 2.30 (1.61, 3.27)*
Male 1.15 (0.93, 1.43) 1.15 (0.92, 1.43) 0.81 (0.59, 1.13) 0.93 (0.66, 1.30)
Black 0.57 (0.43, 0.75)* 0.61 (0.45, 0.82)z 0.89 (0.58, 1.36) 0.90 (0.58, 1.39)
Medicaid 1.26 (0.85, 1.88) 1.19 (0.78, 1.81) 1.53 (0.94, 2.51) 1.50 (0.92, 2.46)
Diabetic ESRD 1.22 (0.96, 1.56) 1.29 (1.01, 1.64)y 1.12 (0.76, 1.67) 1.25 (0.83, 1.88)
No. of cardiovascular conditions 1.28 (1.17, 1.41)* 1.25 (1.14, 1.38)* 1.35 (1.11, 1.64)z 1.28 (1.04, 1.57)y
BMI (reference o19) 1.00 1.00 1.00 1.00
(19, 25) 0.79 (0.50, 1.26) 0.71 (0.45, 1.10) 1.21 (0.52, 2.81) 1.27 (0.52, 3.10)
X25 0.63 (0.40, 0.98)y 0.59 (0.39, 0.90) 1.16 (0.51, 2.67) 1.21 (0.50, 2.96)
Months on dialysis (reference p22) 1.00 1.00 1.00 1.00
(22, 65) 1.20 (0.95, 1.53) 1.19 (0.93, 1.51) 1.52 (0.94, 2.46) 1.71 (1.03, 2.84)y
X65 1.15 (0.83, 1.60) 1.06 (0.76, 1.49) 1.63 (0.97, 2.75) 2.06 (1.20, 3.54)y
Frequent dialysis 0.36 (0.22, 0.61)w 0.56 (0.35, 0.89)y 0.64 (0.31, 1.31) 0.83 (0.42, 1.65)
AMI, acute myocardial infarction; BMI, body mass index; CI, confidence interval; ESRD, end-stage renal disease; HD, hemodialysis.
*Po0.0001.
wPo0.001.
zPo0.005.
yPo 0.05.
Log-rank test P<0.0001
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Figure 1 |Kaplan–Meier analysis of nocturnal hemodialysis
(NHD) therapy patient and conventional hemodialysis (CHD)
control survival from baseline. Patient survival was analyzed as
time until death; observations were censored at the end of follow-
up or transplantation.
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Figure 2 |Kaplan–Meier analysis of short-duration daily
hemodialysis (SDHD) therapy patient and conventional
hemodialysis (CHD) control survival from baseline. Patient
survival was analyzed as time until death; observations were
censored at the end of follow-up or transplantation.
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selection could be an important factor limiting our ability to
detect changes in hospitalization. Our SDHD and NHD
cohorts both had lower hospitalization rates in the year
preceding the switch to frequent HD than did previously
described cohorts,5–7,26,27 making it less likely that hospita-
lization would be reduced by intensifying dialysis therapy and
limiting power to detect such a change even if present.
The possibility that frequent HD may be associated with
an increase in vascular access complications due to more
frequent cannulation has been a concern. Earlier evidence
about this issue has been equivocal.28 Our results, as well as
results from other recent studies, do not indicate that a
significant increase in vascular access complications requiring
hospitalization accompanies use of high-intensity HD. In a
randomized controlled trial recently reported by Culleton
et al.,15 complications related to vascular access did not differ
significantly over a 6-month follow-up between patients
randomized to NHD and those randomized to CHD. In
our study, risk for vascular access–related hospital admissions
was not significantly associated with NHD or SDHD use
compared with matched controls. The events that were
related to vascular access remained a small proportion of the
total hospitalization events observed for frequent HD
patients, limiting the power to detect changes related to
treatment type. Furthermore, many vascular access events
may be managed without hospital admission and are not
counted in these data, making it impossible to rule out an
increase in vascular access events.
Vascular access type is an especially important potential
confounder because it is clearly associated with survival—
better in the case of arteriovenous fistula and worse in the
case of tunneled catheter29–32—and because access type may
also be associated with selection for frequent HD. Some
groups initially required or preferred tunneled dialysis
catheters for NHD. However, a recent report from the
International Quotidian Dialysis Registry shows that all types
of dialysis access are in use for frequent HD.33 In this registry,
the prevalence of catheter use is 21.1% among patients from
the United States receiving SDHD at home and 24.6% for
patients receiving NHD at home. These numbers are similar
to what has been reported in the US CHD cohort from the
Dialysis Outcomes and Practice Patterns Study (DOPPS),
which varied from 17% during DOPPS I (1996–2000) to 27%
in DOPPS II (2002–2003).34 Thus, it does not seem that there
is a large difference in access type between patients receiving
frequent and conventional dialysis therapies at the national
level. However, it is possible that there could be differences
between our frequent dialysis and CHD cohorts, as this
variable was not available for matching.
There is evolving variation in frequency, duration, and
setting of frequent HD treatments. For example, compared
with the treatment patterns described in Table 1, it is likely
that the median number of SDHD sessions/week is now 6
rather than 5, and NHD patients may be more likely to have
5 rather than 6 sessions/week to avoid phosphorus depletion.
The International Quotidian Dialysis Registry, developed to
track treatment and outcomes in the frequent dialysis
population, has recognized this heterogeneity and has
classified patients into five different categories based on the
treatment length, frequency, and location.33 Thus, although
heterogeneity in regimens makes it difficult to compare
frequent dialysis regimens with CHD in large numbers of
patients, it is reflective of current clinical practice. Further-
more, the heterogeneity in treatment regimens would be
likely to obscure rather than exaggerate any differences in
survival or hospitalization by increasing variability within
the frequent dialysis groups.
A randomized controlled trial, such as the ongoing
Frequent Hemodialysis Network randomized trials of NHD
and SDHD, would provide the most definitive evidence
about survival benefit associated with frequent HD. However,
these studies are not powered to examine mortality out-
comes, and recruiting the number of patients needed for such
a study is not considered feasible.35 Given that large-scale
trials on frequent HD versus CHD may never be conducted,36
observational studies can provide important insight. Culleton
et al.15 recommend that data collection for hospitalizations
and vascular access complications should have high priority
in future observational studies. In addition, evolving techno-
logy for frequent HD requires study, as new machines
become available and practice standards evolve.35 In the
meantime, our study adds to existing evidence that NHD
may improve patient survival, which remains the ongoing
primary challenge in provision of dialysis therapy.10,35 In the
light of accumulating evidence of the potential survival
benefit of NHD from this study and others, as well as
estimated cost savings for home NHD compared with in-
center CHD,37 more focus on expanding the use of non-in-
center-based NHD seems warranted.2
METHODS
Data sources and collection
A total of eight clinicians with substantial frequent HD programs
were asked to participate in a special USRDS linked data study.
Three of these clinicians expressed interest in the study but decided
not to participate due to reported difficulties in obtaining
institutional review board approval and/or lack of administrative
help needed to furnish the data requested for the study. Requests
were also circulated to attendees of the 2001 NIH Daily Dialysis
Workshop, but these requests did not yield any additional
participants. Thus, five clinicians provided data to the USRDS
Coordinating Center for patients who had undergone frequent HD
regimens in their programs over the time period of 1997–2006.
These data sets included information about the type of frequent HD
used (NHD or SDHD), number of days/week treatment, number
hours/HD session, start date of frequent HD, and end date if
applicable. This paper analyzes outcomes for 94 patients who were
reported to have used NHD and 43 patients who were reported to
have used SDHD at least 5 times/week for more than 60 days. Most
of the SDHD patients used the PHD System (Aksys, Lincolnshire,
IL, USA).
The USRDS Coordinating Center de-identified the data by
assigning unique USRDS patient identifiers before sending the data
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set to the USRDS Rehabilitation/Quality of Life Special Studies
Center at Emory University. Data for individual patients were then
linked with information available in the updated 2007 USRDS
Standard Analysis Files (SAFs). In addition, two comparison cohorts
of patients using thrice weekly CHD were identified from the
USRDS database using PS analysis. Each patient in both the NHD
and SDHD cohorts was matched to 10 CHD patients. The study was
approved by the Institutional Review Board of Emory University
and the Committee on Human Research at the University of
California, San Francisco.
Patient age, gender, race, and dialysis start date were obtained
from the USRDS Patient SAF, along with Medicaid coverage at
treatment start (yes/no) as an indicator of lower income status.
Clinical characteristics that were documented at treatment start
(primary diagnosis of diabetes, number of existing cardiovascular
conditions (congestive heart failure, coronary artery disease, history
of AMI, cardiac arrest, dysrthythmia, cerebral vascular disease, and
peripheral vascular disease), and body mass index) were also
obtained from the Patient SAF. Information about patients’
treatment modality before start of frequent HD was available in
the Treatment History SAF. Patient mortality data were obtained
from USRDS Patient files that contained death dates through 30
September 2006.
The hospital file in the 2007 SAFs was used to identify hospital
admissions and days. International Classification of Diseases, Ninth
revision, Clinical Modification (ICD-9-CM) codes were used to
identify primary diagnoses associated with hospitalization events.
Cardiovascular-related hospitalization was identified by ICD-9-CM
codes 390-459 (diseases of the circulatory system), 518.4 (acute
pulmonary edema), 276.6 (fluid overload), 785 (symptoms invol-
ving cardiovascular system), 786.5 (chest pain), and 780.2 (syncope
and collapse). Congestive heart failure-related hospitalization was
identified by ICD-9-CM codes 398.01, 402.X1, 404.X1, 404.X3, 422,
425, and 428. Infection-related hospitalization was identified by
ICD-9-CM codes 480-487 (influenza/pneumonia); 038, 790.7, 790.8
(bacteremia/viremia/septicemia); and 472-474.0, 475-477.9, 478.22-
478.24, 480-491, 494, 510-511, 513.0, and 518.6 (respiratory
infection). Vascular access–related hospitalization was identified by
ICD-9-CM codes 996.1, 996.62, and 996.73 (diagnosis codes) and
3895, 3927, 3942, 3943, 3993, 3994, and 8607 (procedure codes).
Occurrence of the major morbid events of AMI (ICD-9-CM codes
410, 410.X0, 410.X1) and stroke (ICD-9-CM codes 430-437) was
identified by first diagnosis codes attached to hospitalization events
in the hospital file.
Statistical analysis
A PS for initiating each of the two frequent HD regimens was
estimated. The baseline was defined as NHD or SDHD start date for
patients in the two cohorts. Baseline was defined as 1 January 2003
for patients in the comparison cohorts because 2003 was the year in
which the largest number of frequent HD patients initiated this
therapy. As we restricted the frequent HD patients to persons who
used this therapy for at least 60 days after baseline, the population
considered for the comparison cohorts was restricted to patients
alive 60 days after the baseline date of 1 January 2003. PS scores were
based on logistic regression models that included the following
covariates: age, gender, race, Medicaid status, diabetic ESRD,
number of cardiovascular comorbid conditions, body mass index,
vintage, number of all-cause, cardiovascular-related and vascular
access–related hospitalizations, and number of days of all-cause,
cardiovascular-related and vascular access–related hospitalization
occurring within a maximum of 365 days before baseline (start of
frequent HD or 2003). The c statistic of the PS model predicting
NHD use was 0.56, and the c statistic of the PS model predicting
SDHD use was 0.60. We matched the 137 frequent HD patients to
CHD patients in a 1:10 ratio. Among them, 119, 13, and 5 frequent
HD patients were matched to CHD patients who had a PS that was
identical to 4, 3, and 2 digits, respectively.
Baseline characteristics of patients who started NHD (n¼ 94)
and matched CHD controls (n¼ 940) were compared by t-test
(continuous variables) and w2-test (categorical variables). Similarly,
baseline characteristics of SDHD patients (n¼ 43) and matched
CHD controls (n¼ 430) were compared by t-test and w2-test. The
association of dialysis modality (NHD versus CHD; SDHD
versus CHD) with risk for death, risk for death or major morbid
event (AMI, stroke), and risk for hospitalization (all cause,
cardiovascular related, CHF related, infection related, and vascular
access related) was examined in multivariable Cox proportional
hazards models. Observations were censored at transplantation or
end of follow-up; in the exploratory analyses of risk for
hospitalization, observations were also censored at death. For death,
the follow-up date was 30 September 2006, the latest date for which
mortality outcomes were available. For the composite end point
(death or major morbid event, that is, AMI, stroke) and for
hospitalization outcomes, the follow-up date was 31 December
2005, the latest date for which hospitalization outcomes were
available. As the proportional hazards assumption was of concern
in the analyses of the SDHD cohort, additional analyses
were performed in which we partitioned the follow-up time
span into an early period (2 years) and a late period (beyond 2
years), and allowed for interval-specific hazard ratios for SDHD
versus controls.
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